Publications by authors named "Andrew D Redfern"

Claim this Profile
E
EMT and cancer: what clinicians should know.
Erik W Thompson, Andrew D Redfern, Simone Brabletz, Geert Berx, Veenoo Agarwal

Nat Rev Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PACT is requisite for prostate cancer cell proliferation.
Dianne J Beveridge, Andrew J Woo, Kirsty L Richardson, Rikki A M Brown, Lisa M Stuart, Andrew D Redfern

Sci Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of genetics and the environment on cancer risk in Indigenous Australians: a narrative review.
Andrew D K Nguyen, Katie Meehan, Andrew D Redfern, Alex Brown, Melanie Robinson

Lancet Reg Health West Pac· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aboriginal and Torres Strait Islander Females and Survival from Breast Cancer.
Alice R T Bergin, Luc Te Marvelde, Roger L Milne, Luis E Lara Gonzalez, Katie Meehan, Andrew D Redfern

Cancer Epidemiol Biomarkers Prev· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinoma.
Tasnuva D Kabir, Samuel Beck, Lisa M Stuart, Ji Li, Rui Hou, Andrew D Redfern

Cell Death Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M Joshua, Shahneen Sandhu, Andrew D Redfern

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
Dickon Hayne, Katherine Ong, Nicole Swarbrick, Steve P McCombie, Andrew Moe, Andrew D Redfern

BJU Int· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unleashing anti-tumour immunity: dietary restriction and exercise interventions adjunct to chemotherapy for cancer patients.
Cristina Crespo-Garcia, John P Campbell, Dennis R Taaffe, Carolyn J Peddle-McIntyre, Emily Jeffery, Andrew D Redfern

Exerc Immunol Rev· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BMP4-Induced Suppression of Breast Cancer Metastasis Is Associated with Inhibition of Cholesterol Biosynthesis.
Lap Hing Chi, Andrew D Redfern, Terry C C Lim Kam Sian, Ian P Street, Allan D Burrows

Int J Mol Sci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study.
Jin-Soo Kim, Dennis R Taaffe, Daniel A Galvão, Timothy D Clay, Andrew D Redfern

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Andrew D Redfern

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of tumor-derived SMAD4 enhances primary tumor growth but not metastasis following BMP4 signalling.
Lap Hing Chi, Andrew D Redfern, Suraya Roslan, Ian P Street, Allan D Burrows

Cell Commun Signal· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival with [Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James P Buteau, Andrew D Redfern

Lancet Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer.
Jin-Soo Kim, Dennis R Taaffe, Daniel A Galvão, Timothy D Clay, Andrew D Redfern

Prostate Cancer Prostatic Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zirconium-labelled girentuximab (Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma.
Mohammed Al-Zubaidi, Pravin Viswambaram, Steve McCombie, Elizabeth Liow, Nat Lenzo, Andrew D Redfern

BMJ Open· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Siao-Nge Hoon, Peter Kh Lau, Alison M White, Max K Bulsara, Patricia D Banks, Andrew D Redfern

Cochrane Database Syst Rev· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M Joshua, Andrew D Redfern

Lancet· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis.
Bedrich L Eckhardt, Yuan Cao, Andrew D Redfern, Lap Hing Chi, Allan D Burrows

Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.
Anabel Sorolla, Edina Wang, Emily Golden, Ciara Duffy, Sónia T Henriques, Andrew D Redfern

Oncogene· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers.
Jessica A Kretzmann, Cameron W Evans, Colette Moses, Anabel Sorolla, Amy L Kretzmann, Andrew D Redfern

Chem Sci· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.
Anabel Sorolla, Edina Wang, Tristan D Clemons, Cameron W Evans, Janice Hc Plani-Lam, Andrew D Redfern

Nanomedicine· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine.
Nicolas H Hart, Daniel A Galvão, Christobel Saunders, Dennis R Taaffe, Kynan T Feeney, Andrew D Redfern

Trials· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.
Andrew D Redfern, Lisa J Spalding, Erik W Thompson

Clin Exp Metastasis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression.
Belinda Yeo, Andrew D Redfern, Kellie A Mouchemore, John A Hamilton, Robin L Anderson

Clin Exp Metastasis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Luca Gianni, Mauro Mansutti, Antonio Anton, Lourdes Calvo, Giancarlo Bisagni, Andrew D Redfern

JAMA Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis